476 related articles for article (PubMed ID: 30689009)
1. [Antithrombotic treatment in acute coronary syndrome and atrial fibrillation].
Darius H; Görge G; Spiecker M; Schinzel H
Herz; 2019 Feb; 44(1):29-34. PubMed ID: 30689009
[TBL] [Abstract][Full Text] [Related]
2. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Darius H
Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
[TBL] [Abstract][Full Text] [Related]
4. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.
Potpara TS; Mujovic N; Proietti M; Dagres N; Hindricks G; Collet JP; Valgimigli M; Heidbuchel H; Lip GYH
Europace; 2020 Jan; 22(1):33-46. PubMed ID: 31603196
[TBL] [Abstract][Full Text] [Related]
6. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Park J; Jung JH; Choi EK; Lee SW; Kwon S; Lee SR; Kang J; Han KD; Park KW; Oh S; Lip GYH
PLoS One; 2022; 17(2):e0264538. PubMed ID: 35213632
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.
Lopes RD; Hong H; Harskamp RE; Bhatt DL; Mehran R; Cannon CP; Granger CB; Verheugt FWA; Li J; Ten Berg JM; Sarafoff N; Gibson CM; Alexander JH
JAMA Cardiol; 2019 Aug; 4(8):747-755. PubMed ID: 31215979
[TBL] [Abstract][Full Text] [Related]
8. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Fanaroff AC; Lopes RD
Prog Cardiovasc Dis; 2021; 69():11-17. PubMed ID: 34883097
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Kuno T; Ueyama H; Takagi H; Ando T; Numasawa Y; Briasoulis A; Fox J; Bangalore S
Am J Cardiol; 2020 Feb; 125(4):521-527. PubMed ID: 31839147
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
Fluschnik N; Becher PM; Schnabel R; Blankenberg S; Westermann D
Herz; 2018 Feb; 43(1):20-25. PubMed ID: 29188358
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen.
Kawakami S; Yasuda S; Ogawa H
J Cardiol; 2020 Jul; 76(1):35-43. PubMed ID: 32389534
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
Vranckx P; Lewalter T; Valgimigli M; Tijssen JG; Reimitz PE; Eckardt L; Lanz HJ; Zierhut W; Smolnik R; Goette A
Am Heart J; 2018 Feb; 196():105-112. PubMed ID: 29421002
[TBL] [Abstract][Full Text] [Related]
13. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
[TBL] [Abstract][Full Text] [Related]
15. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
16. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
[TBL] [Abstract][Full Text] [Related]
17. Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?
Lam DH; Bell SM; Hira RS
Curr Atheroscler Rep; 2018 Jan; 20(1):4. PubMed ID: 29349596
[TBL] [Abstract][Full Text] [Related]
18. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
Vranckx P; Valgimigli M; Eckardt L; Lewalter T; Unikas R; Marin F; Schiele F; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Tijssen J; Goette A
Eur Heart J; 2020 Dec; 41(47):4497-4504. PubMed ID: 32860041
[TBL] [Abstract][Full Text] [Related]
19. Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS.
Badjatiya A; Rao SV
Curr Cardiol Rep; 2019 Jan; 21(1):3. PubMed ID: 30637536
[TBL] [Abstract][Full Text] [Related]
20. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.
Lopes RD; Hong H; Harskamp RE; Bhatt DL; Mehran R; Cannon CP; Granger CB; Verheugt FWA; Li J; Ten Berg JM; Sarafoff N; Vranckx P; Goette A; Gibson CM; Alexander JH
JAMA Cardiol; 2020 May; 5(5):582-589. PubMed ID: 32101251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
